Skip to content

pn_blog-post_alert-logo_hubspot

PN_email_Headers_Alert-Banner

Patients on Cobenfy Show Continued Improvement in 52-Week Trial

2/5/26 12:01 PM

A 52-week open-label trial of antipsychotic Cobenfy (xanomeline-trospium chloride, X/T) found that p...

This is a search field with an auto-suggest feature attached.

There are no suggestions because the search field is empty.

Subscribe Here!

February 2026 FINAL

News From Current Issue

Special Report: Barriers to Rehabilitation After Discharge: A C-L Perspective
The Doctor of Culture
How Conversion Therapy Exploits Parents’ Fears

Read This Week's Update

PN_email_Headers_Update-Banner

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.